Blood-sampling collection prior to surgery may have a significant influence upon biomarker concentrations measured

Clinical Proteomics

Volumn 12, Issue 1, 2015, Pages

  Kahn, Nicolas ^a,c   Riedlinger, Julia ^b   Roeßler, Markus ^b   Rabe, Christina ^b   Lindner, Michael ^d,e   Koch, Ina ^d,e   Schott Hildebrand, Sabine ^d,e   Herth, Felix J ^a,c   Schneider, Marc A ^a,c   Meister, Michael ^a,c   Muley, Thomas R ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c German Center for Lung Research (DZL)   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e German Center for Lung Research (DZL)   (Germany)

Author keywords

Anesthesia induction; Biomarker; Blood specimens; CEA; CYFRA 21 1; Lung cancer; Sampling time points; SCC; SPREC coding

Indexed keywords

BIOLOGICAL MARKER; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ANESTHESIA INDUCTION; ARTERY CATHETER; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; LUNG CANCER; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; SYSTEMIC DISEASE; VEIN PUNCTURE; VERY ELDERLY; YOUNG ADULT;

EID: 84938402806     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/s12014-015-9093-6     Document Type: Article

References (20)

1. Alberg AJ, Ford JG, Samet JM, American College of Chest P. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S-55S.
2. Cho WC. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother Biomed Pharmacother. 2007;61:515-9.
3. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60.
4. Hibel LC, Granger DA, Cicchetti D, Rogosch F. Salivary biomarker levels and diurnal variation: associations with medications prescribed to control children's problem behavior. Child Dev. 2007;78:927-37.
5. Cabrera-Alarcon JL, Carrillo-Vico A, Santotoribio JD, Leon-Justel A, Sanchez-Gil R, Gonzalez-Castro A, et al. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Clin Lab. 2011;57:1011-4.
6. Ebert W, Muley T, Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Anticancer Res. 1996;16:2161-8.
7. Ebert W, Muley T, Trainer C, Dienemann H, Drings P. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC. Anticancer Res. 2002;22:1083-9.
8. Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem. 2002;48:1931-7.
9. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol J Int Soc Oncodev Biol Med. 2003;24:209-18.
10. Muley T, Dienemann H, Ebert W. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res. 2004;24:1953-6.
11. Muley T, Ebert W, Stieber P, Raith H, Holdenrieder S, Nagel D, et al. Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay. Clini Chem Lab Med CCLM/FESCC. 2003;41:95-103.
12. Muley T, Fetz TH, Dienemann H, Hoffmann H, Herth FJ, Meister M, et al. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC. Lung Cancer. 2008;60:408-15.
13. Pujol JL, Molinier O, Ebert W, Daures JP, Barlesi F, Buccheri G, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004;90:2097-105.
14. Stieber P, Hasholzner U, Bodenmuller H, Nagel D, Sunder-Plassmann L, Dienemann H, et al. CYFRA 21-1. A new marker in lung cancer. Cancer. 1993;72:707-13.
15. Stieber P, Zimmermann A, Reinmiedl J, Muller C, Hoffmann H, Dienemann H. CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC). Anticancer Res. 1999;19:2665-8.
16. Betsou F, Lehmann S, Ashton G, Barnes M, Benson EE, Coppola D, et al. Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cospons Am Soc Preventive Oncol. 2010;19:1004-11.
17. Rondina MT, Grissom CK, Men S, Harris ES, Schwertz H, Zimmerman GA, et al. Whole blood flow cytometry measurements of in vivo platelet activation in critically-Ill patients are influenced by variability in blood sampling techniques. Thromb Res. 2012;129:729-35.
18. Trape J, Perez de Olaguer J, Buxo J, Lopez L. Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer. Clin Chem. 2005;51:219-22.
19. Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, et al. Effects of blood collection conditions on ovarian cancer serum markers. PLoS One. 2007;2:e1281.
20. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem Zeitschrift fur klinische Chemie und klinische Biochemie. 1983;21:709-20.